Literature DB >> 32990088

Cardio-oncology for the general physician: 'old' and 'new' cardiovascular toxicities and how to manage them.

Michael Mallouppas1,2, J Malcolm Walker1,2, Avirup Guha3, Rebecca Dobson4, Arjun K Ghosh1,2,5.   

Abstract

Cardio-oncology is the care of cancer patients with cardiovascular disease. The need for a dedicated subspecialty emerged to address heart failure caused by drugs such as anthracyclines and anti-human epidermal growth factor receptor 2 (HER2) therapies, but over time has expanded into an exciting subspecialty with widening horizons. While still dealing with a lot of commonly recognised toxicities, such as heart failure, hypertension and coronary disease, new and revolutionary cancer therapies have been associated with challenging cardiovascular complications, requiring specialist input to manage effectively. Echocardiography is a key investigation, with advanced techniques such as three-dimensional and strain assessment allowing more accurate diagnosis and earlier detection of subtle changes. Cardiac magnetic resonance and biomarkers are useful adjuncts to aid diagnosis and management. With increasing cancer incidence and improved cancer survival rates, it is important that general cardiologists and physicians are aware of cardiac complications associated with cancer and how to manage them.

Entities:  

Keywords:  Cancer; Cardio-oncology; Cardiotoxicity; Heart failure; Myocarditis; Toxicity

Mesh:

Year:  2020        PMID: 32990088     DOI: 10.12968/hmed.2020.0269

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN: 1750-8460            Impact factor:   0.825


  1 in total

1.  Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation.

Authors:  Avirup Guha; Cesar Caraballo; Prantesh Jain; P Elliott Miller; Jocelyn Owusu-Guha; Katherine A A Clark; Eric J Velazquez; Tariq Ahmad; Lauren A Baldassarre; Daniel Addison; Neal L Weintraub; Nihar R Desai
Journal:  ESC Heart Fail       Date:  2021-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.